Benzinga Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients
Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma patients, beating standard treatments with manageable side effects. read more